首页 > 市场调查报告书 > 医疗设备

心血管设备循环系统

市场调查报告书

商品编码

1297802

全球心房颤动市场 - 2023-2030年

Global Atrial Fibrillation Market - 2023-2030

出版日期: 2023年06月15日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

全球心房颤动市场在2022年达到193亿美元，预计到2030年将见证有利可图的增长，达到428亿美元。在2023-2030年的预测期内，全球心房颤动市场预计将呈现10.7%的复合增长率。

心房颤动（A-fib）是一种心律失常（一种不规则的、通常非常快的心律），可导致心脏内的血栓。中风、心力衰竭和其他与心脏有关的问题都会因心房颤动而增加。

在心房颤动期间，心脏的上腔（心房）混乱而不规则地跳动，与下腔（心室）的节奏不一致。许多患有心房颤动的人没有任何症状。反之，心房颤动可引起快速、敲击式的心跳（心悸）、呼吸短促或虚弱。

市场动态

肥胖和心脏疾病负担的增加推动了市场的增长

心房颤动市场受到全球肥胖和心脏疾病发病率上升的推动。此外，心脏病是全世界死亡的主要原因之一，由于生活方式的改变，患心脏病的人数正在激增。肥胖与患心血管疾病（CVD）的风险增加有关，特别是心力衰竭（HF）和冠心病（CHD）。

肥胖增加心血管疾病风险的机制涉及身体成分的变化，可以影响血液动力学和改变心脏结构。脂肪组织产生的促炎症细胞因子可以诱发心脏功能障碍并促进动脉粥样硬化斑块的形成。

缺乏有效治疗心房颤动的策略

由于缺乏对心房颤动发病机制的透彻了解，以及抗心律失常药物治疗的低效率和不良反应，对治疗心房颤动构成了重大障碍。

心房颤动患者的数量不断扩大，对抗凝、抗心律失常药物和控制心率药物等治疗方案的需求不断增加，使正常的卫生保健系统负担加重。此外，对心房颤动和潜在的治疗技术缺乏认识和了解，正在减缓对心房颤动治疗设备和程序的接受。

COVID-19的影响分析

COVID-19对心房颤动的影响是巨大的；根据一项综合研究，心房颤动的发生率在COVID-19患者中占8%，与年龄较大、男性和高血压有关。与没有心房颤动的患者相比，心房颤动患者的全因死亡风险更大。在新诊断的心房颤动患者中也出现了类似的结果。

这些发现突出了心房颤动对COVID-19患者的负面影响，并支持有必要为并发心房颤动的COVID-19患者的预防、诊断和治疗制定独特和有针对性的措施。需要更多的研究来确定监测这些人的最佳方法，特别是抗血栓治疗。

Market Overview

The Global Atrial Fibrillation Market reached US$ 19.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 42.8 billion by 2030. The Global Atrial Fibrillation Market is expected to exhibit a CAGR of 10.7% during the forecast period 2023-2030.

Atrial fibrillation (A-fib) is an arrhythmia (an irregular and typically very fast heart rhythm) that can result in blood clots in the heart. Stroke, heart failure, and other heart-related problems are all increased by atrial fibrillation.

During atrial fibrillation, the heart's top chambers (the atria) beat chaotically and irregularly, out of rhythm with the bottom chambers (the ventricles). Many persons with atrial fibrillation have no symptoms. Atrial fibrillation, conversely, can induce a rapid, hammering heartbeat (palpitations), shortness of breath, or weakness.

Market Dynamics

The Rising Burden of Obesity and Heart Diseases Drives the Market Growth

The atrial fibrillation market is driven by the rising prevalence of obesity and heart diseases across the globe. Additionally, heart diseases are one of the major causes of mortality around the world, and due to the changing lifestyle, the number of people suffering from heart diseases is proliferating. Obesity is associated with an increased risk of developing cardiovascular disease (CVD), particularly heart failure (HF) and coronary heart disease (CHD).

The mechanisms through which obesity increases CVD risk involve changes in body composition that can affect hemodynamics and alters heart structure. Pro-inflammatory cytokines produced by the adipose tissue can induce cardiac dysfunction and promote the formation of atherosclerotic plaques.

Lack of Strategies to Effectively Treat Atrial Fibrillation

The absence of a thorough knowledge of the pathogenesis of atrial fibrillation, as well as the inefficiency and adverse effects associated with antiarrhythmic medication therapy, pose significant obstacles in treating atrial fibrillation.

The expanding number of patients with atrial fibrillation and the growing need to adapt treatment options such as anticoagulation, antiarrhythmic medicines, and rate control medications is increasing the normal health care system load. Furthermore, a lack of awareness and understanding concerning atrial fibrillation and potential therapeutic techniques is slowing the uptake of atrial fibrillation therapy devices and procedures.

COVID-19 Impact Analysis

The influence of COVID-19 on atrial fibrillation was enormous; according to a comprehensive study, the incidence of atrial fibrillation was 8% of COVID-19 patients and was related to older age, male sex, and hypertension. Patients with Atrial Fibrillation had a greater risk of all-cause death than those who did not have atrial fibrillation. Similar results were seen in patients with newly diagnosed atrial fibrillation.

The findings highlight the negative effect of atrial fibrillation in COVID-19 patients and support the necessity for developing unique and targeted measures for the prevention, diagnosis, and therapy of COVID-19 patients with concurrent AF. More research is needed to determine the best ways to monitor these individuals, particularly antithrombotic treatments.

Segment Analysis

The Global Atrial Fibrillation Market is segmented based on treatment type and end user.

The Ambulatory Surgical Center Segment is Expected to Grow During the Forecast Period

The ambulatory surgical center segment is expected to witness good growth of around 33.3% due to enhanced healthcare infrastructure, availability of skilled labor, and affordability. The rising patient pool and growing geriatric population suffering from lifestyle diseases like atherosclerosis and heart failure are expected to propel the market.

However, compared to conventional surgeries, the benefits of minimally invasive surgeries will ultimately lead to segment growth. Benefits, such as reduced surgical pain, injury, hospital stay, higher accuracy, and speedy recovery time, encourage patients to opt for minimally invasive surgeries, which is expected to boost market growth.

Geographical Analysis

North America is the dominating region during the forecast period.

The North American region is expected to dominate the atrial fibrillation market and account for around 41.5% in the forecast period. This is majorly attributed to the rising patient pool in the region and the presence of key players.

The North American region is predicted to lead the worldwide atrial fibrillation market due to the growing acceptance of technologically sophisticated devices and a significant increase in cardiac problems among the aging and general population.

Furthermore, a well-established healthcare infrastructure is projected to support the market's long-term expansion in North America. During the projection period, the North American atrial fibrillation market benefit from patient's high disposable income and growing fibrillation prevalence.

Competitive Landscape

The major global players include: AtriCure, Biosense Webster, Boehringer Ingelheim GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Corporation, Cardio Focus, Endoscopic Technologies, Sanofi Aventis, Abbott, Johnson and Johnson.

Why Purchase the Report?

To visualize the Global Atrial Fibrillation Market segmentation based on the treatment type, end user and region, and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous atrial fibrillation market level data points with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The Global Atrial Fibrillation Market Report Would Provide Approximately 92 Tables, 108 Figures And 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1 Snippet by Treatment Type
3.2 Snippet by End User
3.3 Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1 Increase in Developed Treatments
- 4.1.2. Restraints
  - 4.1.2.1. Lack of Strategies to Effectively Treat Atrial Fibrillation
- 4.1.3. Opportunity
  - 4.1.3.1. Development of Technology
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Post COVID-19 Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Treatment Type

Non-Pharmacological Treatment

Maze Surgery

Catheter Ablation

Radiofrequency Based
HIFU Based
Cryoablation Based
Others

Electric Cardioversion

Pharmacological Treatment

Anti-arrhythmic Drugs

Anti-coagulant Drugs

8. By Region

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 8.1.2. Market Attractiveness Index, By Region
8.2. North America
- 8.2.1. Introduction
- 8.2.2. Key Region-Specific Dynamics
- 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.2.5.1. The U.S.
  - 8.2.5.2. Canada
  - 8.2.5.3. Mexico
8.3. Europe
- 8.3.1. Introduction
- 8.3.2. Key Region-Specific Dynamics
- 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.3.5.1. Germany
  - 8.3.5.2. The UK
  - 8.3.5.3. France
  - 8.3.5.4. Italy
  - 8.3.5.5. Spain
  - 8.3.5.6. Rest of Europe
8.4. South America
- 8.4.1. Introduction
- 8.4.2. Key Region-Specific Dynamics
- 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.4.5.1. Brazil
  - 8.4.5.2. Argentina
  - 8.4.5.3. Rest of South America
8.5. Asia-Pacific
- 8.5.1. Introduction
- 8.5.2. Key Region-Specific Dynamics
- 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 8.5.5.1. China
  - 8.5.5.2. India
  - 8.5.5.3. Japan
  - 8.5.5.4. Australia
  - 8.5.5.5. Rest of Asia-Pacific
8.6. Middle East and Africa
- 8.6.1. Introduction
- 8.6.2. Key Region-Specific Dynamics
- 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country